Comparison · NCT01342367-deaths
SOC Cohort vs Oral ADT Group: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. SOC Cohort vs Oral ADT Group: deaths from any cause. Trial comparisons, record NCT01342367-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01342367-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.267 | 0.142 | 0.444 | wilson | |
| Risk in group 2 | 0.175 | 0.0875 | 0.319 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0917 | -0.0993 | 0.29 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.52 | 0.621 | 3.74 | log | |
| Odds ratio, group 1 over group 2 | 1.71 | 0.543 | 5.41 | log | |
| Number needed to harm, for one more death from any cause on SOC Cohort than on Oral ADT Group | 10.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | SOC Cohort | the standard of care GnRH agonist (SOC) included bicalutamide 50 mg daily with injectable LHRH agonist (e.g. leuprolide or goserelin). for total duration of 2 years and 4 months Bicalutamide given for 4 months RT given 6-8 weeks | 8 | 30 | EG000 |
| Group 2 | Oral ADT Group | Combined androgen blockade in the oral ADT group was bicalutamide 50 mg daily with an oral 5-AR inhibitor (i.e. finasteride 5 mg, or dutasteride 0.5 mg daily), fo rtotal duration of 2 year sand 4 months Bicalutamide given for 4 months RT given 6 8 weeks | 7 | 40 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- from Baseline starting of Radiation, to 3 months post Rt, 6 months, 12 months and 24 months post Radiation, up to a total of 2 years and 4 months.
Source ClinicalTrials.gov
Trial
- Title
- Feasibility of Hormones and Radiation for Intermediate or High Risk Prostate Cancer
- NCT number
- NCT01342367
- Phases
- NA
- Conditions
- Prostate Cancer
- Interventions
- Bicalutamide, Dutasteride, Finasteride, Radiation
- Lead sponsor
- University of Chicago
- Results first posted
- 2021-10-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01342367?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01342367-deaths